We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of Metformin in PCOS: Metabolic and Hormonal Factors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00317928
Recruitment Status : Unknown
Verified August 2001 by Aarhus University Hospital Skejby.
Recruitment status was:  Active, not recruiting
First Posted : April 25, 2006
Last Update Posted : October 11, 2006
Regional Hospital Holstebro
Aarhus University Hospital
Information provided by:
Aarhus University Hospital Skejby

Brief Summary:

Hypothesis: Metformin treatment normalises hormone values and metabolic parameters in women with PCOS. Ovulation is restored and bleeding periods become regular.

Fifty women with PCOS (Rotterdam criteria) are randomised to either placebo or metformin for 6 months. After a wash-out period of 3 months, the opposite treatment is given for another 6 months. Measurements are performed before ech treatment period, every second month during treatment and after completing treatment.

Condition or disease Intervention/treatment
Polycystic Ovary Syndrome Drug: Metformin

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : August 2001
Estimated Study Completion Date : September 2004

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of PCOS
  • Age 20 - 45

Exclusion Criteria:Diabetes

  • Diabetes
  • Hormonal treatment
  • Pregnancy, lactation
  • Periclimacteric

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00317928

Sponsors and Collaborators
Aarhus University Hospital Skejby
Regional Hospital Holstebro
Aarhus University Hospital
Principal Investigator: Ditte Trolle, MD Skejby University Hospital, Aarhus, Denmark

ClinicalTrials.gov Identifier: NCT00317928     History of Changes
Other Study ID Numbers: 160350-1
First Posted: April 25, 2006    Key Record Dates
Last Update Posted: October 11, 2006
Last Verified: August 2001

Keywords provided by Aarhus University Hospital Skejby:
Polycystic Ovary Syndrome
Metabolic Syndrome

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs